Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP-Reference-Cited by-同舟云学术

Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP

Published:2017 Issue:9 Volume:40 Page:1499-1505
ISSN:0918-6158
Container-title:Biological & Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Uchida Mayako¹²,Mori Yasuo³,Nakamura Tsutomu²,Kato Koji³,Kamezaki Kenjiro³,Takenaka Katsuto³,Shiratsuchi Motoaki⁴,Kadoyama Kaori²,Miyamoto Toshihiro³,Akashi Koichi³

Affiliation:

1. Department of Pharmacy, Kyushu University Hospital

2. Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences

3. Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences

4. Department of Medicine and Bioregulatory Science, Kyushu University Graduate School of Medical Sciences

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/40/9/40_b17-00318/_pdf

Reference43 articles.

1. 1) Hesketh PJ. Chemotherapy-induced nausea and vomiting. N. Engl. J. Med., 358, 2482–2494 (2008).

2. 2) Morita S, Kobayashi K, Eguchi K, Matsumoto T, Shibuya M, Yamaji Y, Sakamoto J, Ohashi Y. Influence of clinical parameters on quality of life during chemotherapy in patients with advanced non-small cell lung cancer: application of a general linear model. Jpn. J. Clin. Oncol., 33, 470–476 (2003).

3. 3) Lindley CM, Hirsch JD, O’Neill CV, Transau MC, Gilbert CS, Osterhaus JT. Quality of life consequences of chemotherapy-induced emesis. Qual. Life Res., 1, 331–340 (1992).

4. 4) Jantunen IT, Kataja VV, Muhonen TT. An overview of randomised studies comparing 5-HT₃ receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur. J. Cancer, 33, 66–74 (1997).

5. 5) Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J. Clin. Oncol., 23, 1289–1294 (2005).

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Selective 5-Hydroxytryptamine-3 Receptor and Neurokinin-1 Receptor Antagonists on Hemodynamic Changes and Arrhythmogenic Potential in Patients Receiving Chemotherapy: A Retrospective, Observational Study;Journal of Clinical Medicine;2024-02-01

2. The efficacy of single dose palonosetron in highly emetogenic chemotherapy protocols compared to oral aprepitant and ondansetron;Journal of Pharmacovigilance and Drug Research;2022-09-01

3. Comparison of the antiemetic effect of aprepitant/granisetron and palonosetron combined with dexamethasone in gynecological cancer patients treated with paclitaxel and carboplatin combination regimen;PHARMAZIE;2022

4. Does a single dose of palonosetron have any role in preventing acute chemotherapy-induced nausea and vomiting in pediatric osteosarcoma patients without dexamethasone? A randomized clinical trial;Advances in Clinical and Experimental Medicine;2022-03-16

5. A retrospective study on chemotherapy-induced nausea and vomiting in highly/moderately emetogenic chemotherapy: incidence and prescribing practice;Supportive Care in Cancer;2022-03-15